Category:

Dateline:

Public Company Information:

NASDAQ:

BIIB

US09062X1037

"We believe the data supporting the potential of CIRARA are compelling and that CIRARA can be a first-in-class therapy that gives physicians the ability to meaningfully improve patient outcomes in an area where effective treatments have been few and far between."

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen
(NASDAQ: BIIB) announced today that it has completed an asset purchase
of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous
glyburide). The target indication for CIRARA is large hemispheric
infarction (LHI), a severe form of ischemic stroke where brain swelling
(cerebral edema) often leads to a disproportionately large share of
stroke-related morbidity and mortality. The U.S. Food and Drug
Administration (FDA) recently granted CIRARA Orphan Drug Designation for
severe cerebral edema in patients with acute ischemic stroke. The FDA
has also granted CIRARA Fast Track designation.

Each year approximately 1.7 million ischemic strokes occur across the
U.S., Europe and Japan, and approximately 15 percent of these are LHI
strokes. In pre-clinical studies, CIRARA has been shown to block
SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical
proof-of-concept studies have demonstrated the potential of CIRARA to
reduce brain swelling, disability and the risk of death in patients with
LHI.

“Building on our leading position in multiple sclerosis, spinal muscular
atrophy, and Alzheimer’s disease research, we see a compelling
opportunity in stroke where we can leverage our core expertise in
neuroscience to make a major difference in patient care. CIRARA
represents a potential breakthrough stroke treatment that accelerates
our efforts to build a portfolio of new therapies for neurologic
diseases,” said Michael Ehlers, M.D., Ph.D., Executive Vice President,
Research and Development at Biogen. “We believe the data supporting the
potential of CIRARA are compelling and that CIRARA can be a
first-in-class therapy that gives physicians the ability to meaningfully
improve patient outcomes in an area where effective treatments have been
few and far between.”

This transaction complements Biogen’s broader efforts to build a
portfolio of best-in-class treatments for acute ischemic stroke and
further strengthen its leadership in neuroscience. Biogen currently is
conducting a Phase 2b study to determine whether its monoclonal
antibody natalizumab can help patients with acute ischemic stroke
improve functional outcomes by limiting brain inflammation in the
post-stroke period. If successful, natalizumab and CIRARA
will provide new approaches to treating different populations of stroke
patients.

Biogen plans to continue the development and commercialization of
CIRARA. Under the terms of the agreement, Remedy will share in the cost
of development for the target indication for CIRARA in LHI stroke.
Biogen will make an upfront payment of $120 million to Remedy and may
also pay additional milestone payments and royalties.

About Remedy PharmaceuticalsRemedy Pharmaceuticals, Inc. is
a privately-held, clinical stage pharmaceutical company focused on
developing and bringing lifesaving treatments to people affected by
acute central nervous system (CNS) disease and injuries.

About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative therapies
for people living with serious neurological and neurodegenerative
diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and
today the company has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved treatment
for spinal muscular atrophy; and is at the forefront of neurology
research for conditions including Alzheimer’s disease, Parkinson’s
disease and amyotrophic lateral sclerosis. Biogen also manufactures and
commercializes biosimilars of advanced biologics. For more information,
please visit www.biogen.com.
Follow us on social media – Twitter,
LinkedIn,
Facebook,
YouTube.

Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including
statements relating to the potential benefits and results that may be
achieved through the license agreement with Remedy Pharmaceuticals,
risks and uncertainties associated with drug development and
commercialization, the potential benefits, safety and efficacy of
investigational drugs including CIRARA and natalizumab and the
anticipated completion and timing of the transaction. These
forward-looking statements may be accompanied by words such as
“anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,”
“intend,” “may,” “plan,” “potential,” “possible,” “will” and other words
and terms of similar meaning. You should not place undue reliance on
these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including, without limitation: risks that the transaction will be
completed in a timely manner or at all; uncertainty as to whether the
anticipated benefits of the transaction can be achieved; risks of
unexpected costs or delays; uncertainty of success in the development
and potential commercialization of natalizumab and/or CIRARA, which may
be impacted by, among other things, unexpected concerns that may arise
from additional data or analysis, the occurrence of adverse safety
events, failure to obtain regulatory approvals in certain jurisdictions,
failure to protect and enforce our data, intellectual property and other
proprietary rights and uncertainties relating to intellectual property
claims and challenges; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our expectations
in any forward-looking statement. Investors should consider this
cautionary statement, as well as the risk factors identified in Biogen’s
most recent annual or quarterly report and in other reports Biogen has
filed with the U.S. Securities and Exchange Commission. These statements
are based on our current beliefs and expectations and speak only as of
the date of this press release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result of
new information, future developments or otherwise.